Artemisinins, new miconazole potentiators resulting in increased activity against Candida albicans biofilms

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 421-426

  De Cremer, Kaat ^a,b   Lanckacker, Ellen ^c   Cools, Tanne L ^a   Bax, Marijke ^a   De Brucker, Katrijn ^a   Cos, Paul ^c   Cammue, Bruno P A ^a,b   Thevissen, Karin ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTHELMINTIC AGENT; ANTIINFECTIVE AGENT; ARTESUNATE; BITHIONATE DISODIUM; BROXYQUINOLINE; CASPOFUNGIN; CRYSTAL VIOLET; DIHYDROARTEMISININ; FLUCONAZOLE; HEXACHLOROPHENE; MICONAZOLE; MITUMOMAB; NITROXOLINE; PYRVINIUM EMBONATE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT; ARTEMISININ DERIVATIVE; ECHINOCANDIN; LIPOPEPTIDE;

ANTIFUNGAL ACTIVITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; DRUG STRUCTURE; MITOCHONDRION; NONHUMAN; PLASMODIUM FALCIPARUM; RESPIRATORY CHAIN; CANDIDIASIS; DRUG EFFECTS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ARTEMISININS; BIOFILMS; CANDIDA ALBICANS; CANDIDIASIS; DRUG SYNERGISM; ECHINOCANDINS; FLUCONAZOLE; HEXACHLOROPHENE; LIPOPEPTIDES; MICONAZOLE; MICROBIAL SENSITIVITY TESTS; PYRVINIUM COMPOUNDS; REACTIVE OXYGEN SPECIES;

EID: 84920158561     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04229-14     Document Type: Article

References (44)

1. Ramage G, Rajendran R, Sherry L, Williams C. 2012. Fungal biofilm resistance. Int J Microbiol 2012:528521. http://dx.doi.org/10.1155/2012/528521.
2. Lewis K. 2008. Multidrug tolerance of biofilms and persister cells. Curr Top Microbiol Immunol 322:107-131.
3. Lebeaux D, Fernández-Hidalgo N, Chauhan A, Lee S, Ghigo J-M, Almirante B, Beloin C. 2014. Management of infections related to totally implantable venous-access ports: challenges and perspectives. Lancet Infect Dis 14:146-159. http://dx.doi.org/10.1016/S1473-3099(13)70266-4.
4. Tumbarello M, Fiori B, Trecarichi EM, Posteraro P, Losito AR, De Luca A, Sanguinetti M, Fadda G, Cauda R, Posteraro B. 2012. Risk factors and outcomes of candidemia caused by biofilm-forming isolates in a tertiary care hospital. PLoS One 7:e33705. http://dx.doi.org/10.1371/journal.pone.0033705.
5. Rautemaa R, Ramage G. 2011. Oral candidosis-clinical challenges of a biofilm disease. Crit Rev Microbiol 37:328-336. http://dx.doi.org/10.3109/1040841X.2011.585606.
6. Alves MJ, Barreira JC, Carvalho I, Trinta L, Pereira L, Ferreira IC, Pintado M. 2014. Propensity for biofilm formation by clinical isolates from urinary tract infections: developing a multifactorial predictive model to improve the antibiotherapy. J Med Microbiol 63:471-477. http://dx .doi.org/10.1099/jmm.0.071746-0.
7. Ramage G, Williams C. 2013. The clinical importance of fungal biofilms. Adv Appl Microbiol 84:27-83. http://dx.doi.org/10.1016/B978-0-12-407673-0.00002-3.
8. Harriott MM, Noverr MC. 2011. Importance of Candida-bacterial polymicrobial biofilms in disease. Trends Microbiol 19:557-563. http://dx.doi.org/10.1016/j.tim.2011.07.004.
9. Lim CS-Y, Rosli R, Seow HF, Chong PP. 2012. Candida and invasive candidiasis: back to basics. Eur J Clin Microbiol Infect Dis 31:21-31. http: //dx.doi.org/10.1007/s10096-011-1273-3.
10. Chopra V, Marotta F, Kumari A, Bishier MP, He F, Zerbinati N, Agarwal C, Naito Y, Tomella C, Sharma ASU. 2013. Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs itraconazole. J Biol Regul Homeost Agents 27:875-882.
11. Marchaim D, Lemanek L, Bheemreddy S, Kaye KS, Sobel JD. 2012. Fluconazole-resistant Candida albicans vulvovaginitis. Obstet Gynecol 120:1407-1414. http://dx.doi.org/10.1097/AOG.0b013e31827307b2.
12. Gallè F, Sanguinetti M, Colella G, Di Onofrio V, Torelli R, Rossano F, Liguori G. 2011. Oral candidosis: characterization of a sample of recurrent infections and study of resistance determinants. New Microbiol 34: 379-389.
13. Marcos-Arias C, Eraso E, Madariaga L, Carrillo-Muñoz AJ, Quindós G. 2012. In vitro activities of new triazole antifungal agents, posaconazole and voriconazole, against oral Candida isolates from patients suffering from denture stomatitis. Mycopathologia 173:35-46. http://dx.doi.org/10.1007/s11046-011-9460-4.
14. Rosa MI, Silva BR, Pires PS, Silva FR, Silva NC, Souza SL, Madeira K, Panatto AP, Medeiros LR. 2013. Weekly fluconazole therapy for recurrent vulvovaginal candidiasis: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 167:132-136. http://dx.doi.org/10.1016/j.ejogrb.2012.12.001.
15. Vazquez JA. 2010. Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection. HIV AIDS (Auckl) 2:89-101. http://dx.doi.org/10.2147/HIV.S6660.
16. Vazquez JA. 2000. Therapeutic options for the management of oropharyngeal and esophageal candidiasis in HIV/AIDS patients. HIV Clin Trials 1:47-59. http://dx.doi.org/10.1310/T7A7-1E63-2KA0-JKWD.
17. Taff HT, Mitchell KF, Edward JA, Andes DR. 2013. Mechanisms of Candida biofilm drug resistance. Future Microbiol 8:1325-1337. http://dx.doi.org/10.2217/fmb.13.101.
18. Delattin N, Cammue B, Thevissen K. 2014. Reactive oxygen speciesinducing antifungal agents and their activity against fungal biofilms. Future Med Chem 6:77-90. http://dx.doi.org/10.4155/fmc.13.189.
19. Butler MS, Cooper MA. 2011. Antibiotics in the clinical pipeline in 2011. J Antibiot (Tokyo) 64:413-425. http://dx.doi.org/10.1038/ja.2011.44.
20. Delattin N, De Brucker K, Vandamme K, Meert E, Marchand A, Chaltin P, Cammue BP, Thevissen K. 2014. Repurposing as a means to increase the activity of amphotericin B and caspofungin against Candida albicans biofilms. J Antimicrob Chemother 69:1035-1044. http://dx.doi.org/10.1093/jac/dkt449.
21. LaFleur MD, Lucumi E, Napper AD, Diamond SL, Lewis K. 2011. Novel high-throughput screen against Candida albicans identifies antifungal potentiators and agents effective against biofilms. J Antimicrob Chemother 66:820-826. http://dx.doi.org/10.1093/jac/dkq530.
22. Lafleur MD, Sun L, Lister I, Keating J, Nantel A, Long L, Ghannoum M, North J, Lee RE, Coleman K, Dahl T, Lewis K. 2013. Potentiation of azole antifungals by 2-adamantanamine. Antimicrob Agents Chemother 57:3585-3592. http://dx.doi.org/10.1128/AAC.00294-13.
23. Siles S, Srinivasan A, Pierce CG, Lopez-Ribot JL, Ramasubramanian AK. 2013. High-throughput screening of a collection of known pharmacologically active small compounds for the identification of Candida albicans biofilm inhibitors. Antimicrob Agents Chemother 57:3681-3687. http://dx.doi.org/10.1128/AAC.00680-13.
24. Kaneko Y, Fukazawa H, Ohno H, Miyazaki Y. 2013. Combinatory effect of fluconazole and FDA-approved drugs against Candida albicans. J Infect Chemother 19:1141-1145. http://dx.doi.org/10.1007/s10156-013-0639-0.
25. Spitzer M, Griffiths E, Blakely KM, Wildenhain J, Ejim L, Rossi L, De Pascale G, Curak J, Brown E, Tyers M, Wright GD. 2011. Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole. Mol Syst Biol 7:499. http://dx.doi.org/10.1038/msb.2011.31.
26. Sekhon BS. 2013. Repositioning drugs and biologics: retargeting old/ existing drugs for potential new therapeutic applications. J Pharm Educ Res 4:1-15.
27. Bink A. 2011. Anti-biofilm strategies: how to eradicate Candida biofilms? Open Mycol J 5:29-38. http://dx.doi.org/10.2174/1874437001105010029.
28. Fonzi WA, Irwin MY. 1993. Isogenic strain construction and gene mapping in Candida albicans. Genetics 134:717-728.
29. Van den Driessche F, Rigole P, Brackman G, Coenye T. 2014. Optimization of resazurin-based viability staining for quantification of microbial biofilms. J Microbiol Methods 98:31-34. http://dx.doi.org/10.1016/j.mimet.2013.12.011.
30. Iraqui I, Garcia-Sanchez S, Aubert S, Dromer F, Ghigo JM, D'Enfert C, Janbon G. 2005. The Yak1p kinase controls expression of adhesins and biofilm formation in Candida glabrata in a Sir4p-dependent pathway. Mol Microbiol 55:1259-1271. http://dx.doi.org/10.1111/j.1365-2958.2004.04475.x.
31. O'Brien J, Wilson I, Orton T, Pognan F. 2000. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 267:5421-5426. http://dx.doi.org/10.1046/j.1432-1327.2000.01606.x.
32. Odds FC. 2003. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 52:1. http://dx.doi.org/10.1093/jac/dkg301.
33. Kimbrough RD. 1973. Review of the toxicity of hexachlorophene, including its neurotoxicity. J Clin Pharmacol 13:439-444.
34. Smith TC, Kinkel AW, Gryczko CM, Goulet JR. 1976. Absorption of pyrvinium pamoate. Clin Pharmacol Ther 19:802-806.
35. World Health Organization. 2010. Guidelines for the treatment of malaria, 2nd ed. WHO, Geneva, Switzerland.
36. O'Neill PM, Barton VE, Ward SA. 2010. The molecular mechanism of action of artemisinin-the debate continues. Molecules 15:1705-1721. http://dx.doi.org/10.3390/molecules15031705.
37. Klonis N, Creek DJ, Tilley L. 2013. Iron and heme metabolism in Plasmodium falciparum and the mechanism of action of artemisinins. Curr Opin Microbiol 16:722-727. http://dx.doi.org/10.1016/j.mib.2013.07.005.
38. Wang J, Huang L, Li J, Fan Q, Long Y, Li Y, Zhou B. 2010. Artemisinin directly targets malarial mitochondria through its specific mitochondrial activation. PLoS One 5:e9582. http://dx.doi.org/10.1371/journal.pone.0009582.
39. Krishna S, Pulcini S, Moore CM, Teo BH-Y, Staines HM. 2014. Pumped up: reflections on PfATP6 as the target for artemisinins. Trends Pharmacol Sci 35:4-11. http://dx.doi.org/10.1016/j.tips.2013.10.007.
40. Li W, Mo W, Shen D, Sun L, Wang J, Lu S, Gitschier JM, Zhou B. 2005. Yeast model uncovers dual roles of mitochondria in the action of artemisinin. PLoS Genet 1:e36. http://dx.doi.org/10.1371/journal.pgen.0010036.
41. Moore CM, Hoey EM, Trudgett A, Timson DJ. 2011. Artemisinins act through at least two targets in a yeast model. FEMS Yeast Res 11:233-237. http://dx.doi.org/10.1111/j.1567-1364.2010.00706.x.
42. Alenquer M, Tenreiro S, Sá-Correia I. 2006. Adaptive response to the antimalarial drug artesunate in yeast involves Pdr1p/Pdr3p-mediated transcriptional activation of the resistance determinants TPO1 and PDR5. FEMS Yeast Res 6:1130-1139. http://dx.doi.org/10.1111/j.1567-1364.2006.00095.x.
43. Vandenbosch D, Braeckmans K, Nelis HJ, Coenye T. 2010. Fungicidal activity of miconazole against Candida spp. biofilms. J Antimicrob Chemother 65:694-700. http://dx.doi.org/10.1093/jac/dkq019.
44. Bink A, Vandenbosch D, Coenye T, Nelis H, Cammue BP, Thevissen K. 2011. Superoxide dismutases are involved in Candida albicans biofilm persistence against miconazole. Antimicrob Agents Chemother 55:4033-4037. http://dx.doi.org/10.1128/AAC.00280-11.